Owners, management and financials
CVR: 28301022
DKK 0
Gross profit
Net result: DKK 0
PENSIONSKASSEN FOR TEKNIKUM- OG DIPLOMINGENIØRER (33,33-49,99%), LÆRERNES PENSION, FORSIKRINGSAKTIESELSKAB (15-19,99%)
CVR · view owners
Ahmet Turan Kayhan
Board: Andrea Panzieri (chair) and 2 members
CVR · view management
Active
Founded 16 December 2004
CVR · view overview
No headcount reported
Director registered: Ahmet Turan Kayhan
CVR · 31/01/2023
View the full event history
K/S BI BIOMEDICAL VENTURE IV is a Danish company of the type Kommanditselskab based in København K, founded in 2004. The company is registered under the industry Anden finansiel formidling i.a.n.. The management consists of Ahmet Turan Kayhan. The board consists of Andrea Panzieri (chair), Allan Funk Nissen and Ahmet Turan Kayhan. The company is owned by PENSIONSKASSEN FOR TEKNIKUM- OG DIPLOMINGENIØRER and LÆRERNES PENSION, FORSIKRINGSAKTIESELSKAB. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK 0 the year before. Equity in the 2025 report amounted to DKK 8,000.
Selskabets formål er at foretage investeringer i K/S BI BIOMEDICAL VENTURE ANNEX I,II og III samt sådanne selskabet, som K/S BI BIOMEDICAL VENTURE ANNEX I, II og III investerer i. K/S BI BIOMEDICAL VENTURE ANNEX I, II og III\'s formål er at foretage investeringer i ejerandele i, herunder warrants (tegningsoptioner), eller yde lån til et eller flere unoterede erhvervsdrivende biomedicinske eller bioteknologiske selskaber fortrinsvis i Norden, England, Irland, Tyskland, Frankrig, Holland, Belgien og Luxembourg. Selskaberne kan eje såvel majoritets- som minoritetsposter i sådanne selskaber. Selskaberne kan anbringe ledig kapital i skandinaviske statsobligationer med kort løbetid, i statsgældsbeviser og som kontante indskud i pengeinstittutter. Yderligere kan selskaberne besidde aktier optaget til omsætning på et reguleret marked som følge af en optagelse til omsætning af et porteføljeselskabs aktier eller som vederlag i forbindelse med salg af porteføljeselskaber
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | - | 0 | 8 t. | 8 t. | - | |
| 202401/01/2024 – 31/12/2024 | - | 0 | 8 t. | 8 t. | - | |
| 202301/01/2023 – 31/12/2023 | - | 0 | 8 t. | 8 t. | - | |
| 202201/01/2022 – 31/12/2022 | 0 | -4 t. | 8 t. | 8 t. | - | |
| 202101/01/2021 – 31/12/2021 | 0 | -39 t. | 12 t. | 12 t. | - | |
| 202001/01/2020 – 31/12/2020 | - | -4.5 mio. | 2.9 mio. | 2.9 mio. | - | |
| 201901/01/2019 – 31/12/2019 | - | -20.4 mio. | 7.4 mio. | 7.4 mio. | - | |
| 201801/01/2018 – 31/12/2018 | - | -3.7 mio. | 28.5 mio. | 28.5 mio. | - | |
| 201701/01/2017 – 31/12/2017 | - | -915 t. | 40.7 mio. | 40.7 mio. | - | |
| 201601/01/2016 – 31/12/2016 | - | -27.5 mio. | 42.3 mio. | 42.3 mio. | - | |
| 201501/01/2015 – 31/12/2015 | - | 66.3 mio. | 183.5 mio. | 179.1 mio. | - | |
| 201401/01/2014 – 31/12/2014 | - | 20.8 mio. | 125.9 mio. | 125.8 mio. | - | |
| 201301/01/2013 – 31/12/2013 | - | 3.2 mio. | 127.5 mio. | 127.5 mio. | - | |
| 201201/01/2012 – 31/12/2012 | - | 28.9 mio. | 161.3 mio. | 161.3 mio. | - |
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreThe CVR number of K/S BI BIOMEDICAL VENTURE IV is 28301022.
K/S BI BIOMEDICAL VENTURE IV is owned by PENSIONSKASSEN FOR TEKNIKUM- OG DIPLOMINGENIØRER and LÆRERNES PENSION, FORSIKRINGSAKTIESELSKAB.
The management of K/S BI BIOMEDICAL VENTURE IV consists of Ahmet Turan Kayhan.
The board of K/S BI BIOMEDICAL VENTURE IV consists of Andrea Panzieri, Allan Funk Nissen and Ahmet Turan Kayhan, with Andrea Panzieri as chair.
In 2025, K/S BI BIOMEDICAL VENTURE IV reported a gross profit of DKK 0.
K/S BI BIOMEDICAL VENTURE IV was founded on 16 December 2004.
Claim this page to add your logo and social links. Free to get started.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2025. Gross profit came to DKK 0, and the net result was DKK 0.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2024. Gross profit came to DKK 0, and the net result was DKK 0.
As of May 23, 2025, Allan Funk Nissen has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of May 23, 2025, Mikael Kortegaard Larsen has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2023. Gross profit came to DKK 0, and the net result was DKK 0.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2022. Revenue came to DKK 0, and the net result was DKK -4,000.
As of May 25, 2023, EY Godkendt Revisionspartnerselskab has stepped down as auditor of K/S BI BIOMEDICAL VENTURE IV.
As of January 31, 2023, Ahmet Turan Kayhan has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of January 31, 2023, Kurt Hangaard has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of January 31, 2023, Ahmet Turan Kayhan is registered as director of K/S BI BIOMEDICAL VENTURE IV.
As of January 31, 2023, Kurt Hangaard has stepped down as director of K/S BI BIOMEDICAL VENTURE IV.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -39,000.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2020. The net result was DKK -4,540,000.
As of April 15, 2021, EY Godkendt Revisionspartnerselskab has been appointed auditor of K/S BI BIOMEDICAL VENTURE IV.
As of April 15, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of K/S BI BIOMEDICAL VENTURE IV.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2019. Gross profit came to DKK -20,411,000, and the net result was DKK -20,416,000.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2018. Gross profit came to DKK -3,713,000, and the net result was DKK -3,718,000.
As of January 7, 2019, Kurt Hangaard has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of January 7, 2019, Sanne Fredenslund has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of January 7, 2019, Kurt Hangaard is registered as director of K/S BI BIOMEDICAL VENTURE IV.
As of January 7, 2019, Sanne Fredenslund has stepped down as director of K/S BI BIOMEDICAL VENTURE IV.
As of June 7, 2018, Sanne Fredenslund has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of June 7, 2018, Lars Thomas Gunnarsson has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of June 7, 2018, Sanne Fredenslund is registered as director of K/S BI BIOMEDICAL VENTURE IV.
As of June 7, 2018, Lars Thomas Gunnarsson has stepped down as director of K/S BI BIOMEDICAL VENTURE IV.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2017. Gross profit came to DKK -913,000, and the net result was DKK -915,000.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2016. Gross profit came to DKK -27,492,000, and the net result was DKK -27,494,000.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2015. Gross profit came to DKK 66,330,000, and the net result was DKK 66,330,000.
As of May 6, 2016, Lars Thomas Gunnarsson has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of May 6, 2016, Kenneth Bering Hansen has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of May 6, 2016, Lars Thomas Gunnarsson is registered as director of K/S BI BIOMEDICAL VENTURE IV.
As of May 6, 2016, Kenneth Bering Hansen has stepped down as director of K/S BI BIOMEDICAL VENTURE IV.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2014. Gross profit came to DKK 20,757,000, and the net result was DKK 20,757,000.
As of December 10, 2014, Kenneth Bering Hansen has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of December 10, 2014, Andrea Panzieri has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of December 10, 2014, Mikael Kortegaard Larsen has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of December 10, 2014, Kenneth Bering Hansen is registered as director of K/S BI BIOMEDICAL VENTURE IV.
As of December 10, 2014, Bo Foged has stepped down as director of K/S BI BIOMEDICAL VENTURE IV.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2013. Gross profit came to DKK 3,185,000, and the net result was DKK 3,185,000.
K/S BI BIOMEDICAL VENTURE IV has published its annual report for 2012. Gross profit came to DKK 28,878,000, and the net result was DKK 28,878,000.
As of May 16, 2013, Børge Obel has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of May 16, 2013, Carl Jørgen Dan Jensen has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of May 16, 2013, Bent Pedersen has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of May 16, 2013, David Raymond Ansell has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of May 16, 2013, David Richard Hexter has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of November 17, 2011, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of K/S BI BIOMEDICAL VENTURE IV.
As of November 17, 2011, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of K/S BI BIOMEDICAL VENTURE IV.
As of October 6, 2011, Børge Obel has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of October 6, 2011, Carl Jørgen Dan Jensen has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of October 6, 2011, Bent Pedersen has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of October 6, 2011, David Raymond Ansell has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of October 6, 2011, David Richard Hexter has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of October 6, 2011, Uffe Ellemann-Jensen has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of May 2, 2011, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of K/S BI BIOMEDICAL VENTURE IV.
As of May 2, 2011, EY Godkendt Revisionspartnerselskab has stepped down as auditor of K/S BI BIOMEDICAL VENTURE IV.
As of May 3, 2010, Lars Christian Bruhn has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of February 4, 2010, Bo Foged is registered as director of K/S BI BIOMEDICAL VENTURE IV.
As of February 4, 2010, Thomas Tscherning has stepped down as director of K/S BI BIOMEDICAL VENTURE IV.
As of January 7, 2009, Thomas Tscherning is registered as director of K/S BI BIOMEDICAL VENTURE IV.
As of January 7, 2009, Jesper Zeuthen has stepped down as director of K/S BI BIOMEDICAL VENTURE IV.
As of September 4, 2008, Lars Kolind has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of April 28, 2008, EY Godkendt Revisionspartnerselskab has been appointed auditor of K/S BI BIOMEDICAL VENTURE IV.
As of April 28, 2008, CJ Partnership I/S has stepped down as auditor of K/S BI BIOMEDICAL VENTURE IV.
As of January 7, 2008, PENSIONSKASSEN FOR TEKNIKUM- OG DIPLOMINGENIØRER is registered as an owner of K/S BI BIOMEDICAL VENTURE IV with an ownership share of 33%.
As of January 7, 2008, LÆRERNES PENSION, FORSIKRINGSAKTIESELSKAB is registered as an owner of K/S BI BIOMEDICAL VENTURE IV with an ownership share of 15%.
As of April 30, 2007, Lars Christian Bruhn has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of April 30, 2007, Asger Ib Mardahl-Hansen has left the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of April 25, 2005, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has stepped down as auditor of K/S BI BIOMEDICAL VENTURE IV.
As of December 16, 2004, REVISIONS- OG FORVALTNINGS- INSTITUTET, AKTIESELSKAB has been appointed auditor of K/S BI BIOMEDICAL VENTURE IV.
As of December 16, 2004, CJ Partnership I/S has been appointed auditor of K/S BI BIOMEDICAL VENTURE IV.
As of December 16, 2004, Lars Kolind has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of December 16, 2004, Asger Ib Mardahl-Hansen has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of December 16, 2004, Uffe Ellemann-Jensen has joined the board of directors of K/S BI BIOMEDICAL VENTURE IV.
As of December 16, 2004, Jesper Zeuthen is registered as director of K/S BI BIOMEDICAL VENTURE IV.
K/S BI BIOMEDICAL VENTURE IV was founded on December 16, 2004.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at drive forretning med digital markedsføring og strategi samt enhver i forbindelse hermed stående virksomhed.
Companies in the same industry and area
CVR 38168487
CVR 38168509
CVR 45365123
CVR 42904007
CVR 41201886
